GenXys, the global leader in precision prescribing software with embedded pharmacogenetic (PGx) data, is teaming up with Manchester University in northern Indiana for pharmacogenomics awareness and education.
Pharmacogenomics is a breakthrough science that uses an individual’s genetic markers to customize and optimize their medication therapy.
Together, GenXys and Manchester will help drive global recognition of PGx-informed prescribing decisions and in support of expanding use of PGx. This includes pending legislation in the United States known as the Right Drug Dose Now Act.
The partnership will also enable GenXys' expertise and proprietary algorithms to support expansion of genetically informed medication review capabilities in Manchester’s educational and research space.
This partnership will further students’ learning about evidence-based precision prescribing options for patients, ultimately leading to better health outcomes and empowering the next generation of clinicians to seamlessly utilize PGx in patient care.
Manchester is a national leader in pharmacogenomics education and research. It has on-campus and online master’s degree programs in PGx, offers a dual degree in pharmacy (Pharm.D.) and pharmacogenomics (MS in PGx), as well as a graduate certificate in PGx. Its pharmacogenomics program is based at Manchester University Fort Wayne.
"As a national leader in pharmacogenetic and clinical education, Manchester University looks to partner with leading-edge technology companies that further the advancement of PGx for better health outcomes," says David Kisor, PharmD, FCP, Professor of Pharmaceutical Sciences and Pharmacogenomics, Director of Pharmacogenomics at MU. "It is recognized that more than 95 percent of the population has at least one PGx variant, and large percentages of patients receiving medications across therapeutic areas do not respond adequately with an initial medication leading to trial-and-error prescribing.
